Thursday, November 30, 2023
Ascendis Pharma A/S (Nasdaq: ASND) has recently revealed an exclusive license agreement with Teijin Limited to advance the development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP, specifically targeting endocrinology rare diseases in Japan.
Jan Mikkelsen, Ascendis Pharma's President and CEO, expressed satisfaction with the partnership, highlighting Teijin Pharma's expertise in obtaining regulatory approval and commercializing rare disease and endocrinology product candidates in Japan. Mikkelsen emphasized that the collaboration signifies a significant stride towards achieving a global presence for Ascendis Pharma's current Endocrinology Rare Disease portfolio, aiming to address unmet medical needs among Japanese patients.
Ascendis Pharma's innovative TransCon technology platform, praising the suite of product candidates as highly differentiated with best-in-class potential. Uchikawa anticipated that the partnership would greatly contribute to advancing Teijin Limited's healthcare business vision, especially in addressing issues faced by patients, families, and communities dealing with rare and intractable diseases.
According to the agreement's terms, Ascendis Pharma is set to receive an upfront payment of $70 million, coupled with potential development and regulatory milestones totaling up to $175 million, transfer pricing, and additional commercial milestones. Furthermore, Ascendis Pharma stands to gain royalties on net sales in Japan, ranging up to the mid-20s percent, with variations based on the specific product.
Source: globenewswire.com
